135 completed, 33 unknown, 23 recruiting, 17 not yet recruiting. 238 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 238 | Completed 135, Unknown 33, Recruiting 23, Not yet recruiting 17, Terminated 13, Withdrawn 9, Active not recruiting 6, Enrolling by invitation 2 |
Follow Lacrimal Apparatus Diseases: new trials by email Literature Review of Lacrimal Apparatus Diseases trials Research Report on Lacrimal Apparatus Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cooling Eyedrops for Dry Eye TRYPTYR Eye Drops, Purilens Plus Non-Preserved Saline Eye Drops - Dry Eye | Phase 4 | Not yet recruiting | University of California, Berkeley | 50 | 2026-11-01 | 2026-10-26 |
| Evaporative Dry Eye acoltremon 0.003%. - Dry Eye, Evaporative Dry Eye | Phase 4 | Not yet recruiting | Southern College of Optometry | 41 | 2026-10-26 | 2026-10-28 |
| Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003% acoltremon 0.003% - Dry Eye, Contact Lens Discomfort | Phase 4 | Not yet recruiting | Eye Research Associates, LLC | 50 | 2026-10-10 | 2026-10-08 |
| Switching From Preserved Glaucoma Therapy to Preservative-Free ZOLYMBUS preservative free ZOLYMBUS™ 0.01%. - Eye Drops Self-instillation, Glaucoma | Phase 4 | Not yet recruiting | Southern College of Optometry | 40 | 2026-10-05 | 2026-09-28 |
| Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain acoltremon ophthalmic solution 0.003% - Ocular Pain, Dry Eye | Phase 4 | Not yet recruiting | University of South Florida | 28 | 2026-10-01 | 2026-10-06 |
| Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery LACRIFILL® Canalicular Gel administration, Sham lacrimal canalicular procedure - Dry Eye, Dry Eye Disease (DED) | Phase 4 | Not yet recruiting | Medical University of Vienna | 25 | 2026-09-15 | 2026-09-09 |
| Evaluation of Lacrifill Lacrifill, Saline - Dry Eye, Ocular Surface Disease | Phase 4 | Recruiting | Eye Research Associates, LLC | 40 | 2026-09-02 | 2026-09-25 |
| Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease Standard of Care (SOC), Lyophilized Amnion Membrane Disc Allograft - Dry Eye Disease (DED) | Phase 4 | Withdrawn | Cellution Biologics | 2026-09-01 | 2026-08-27 | |
| Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks Vevye®, Cyclosporine emulsion - Dry Eye Disease (DED) | Phase 4 | Not yet recruiting | Baylor College of Medicine | 60 | 2026-09-01 | 2026-06-03 |
| Evaluation of Ophtholic Ultra for Ocular Surface Protection After Cataract Surgery Ophtholic Ultra, Standard postoperative therapy without lubricating eye drops - Dry Eye Disease (DED) | Phase 4 | Active not recruiting | Kazakh Eye Research Institute | 60 | 2026-08-24 | 2026-10-09 |
| BL-RX01-TFSTAB-1402 Determine the ability of the iTrace™, BOSA™, OPD-Scan III, and IDRA to detect tear film stability utilizing Miebo® - Dry Eye | Phase 4 | Recruiting | Vance Thompson Vision | 20 | 2026-08-01 | 2026-08-27 |
| The Effectiveness of Systane PRO Preservative Free Verses Blink Triple Care Preservative Free Systane PRO, Blink tears - Dry Eye Disease (DED) | Phase 4 | Recruiting | Gordon Schanzlin New Vision | 30 | 2026-07-17 | 2026-08-04 |
| TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED) TRYPTYR (Acoltremon ophthalmic solution 0.003%) - Dry Eye Disease (DED) | Phase 4 | Recruiting | NYU Langone Health | 50 | 2026-07-06 | 2026-07-28 |
| Randomized Clinical Trial of Artificial Tears With and Without Preservatives in Patients With Dry Eye Disease Carboxy methyl cellulose, Preservative free Carboxy methyl cellulose - Dry Eye Disease (DED) | Phase 4 | Not yet recruiting | Pokhara Academy of Health Sciences, Western Regional Hospital | 80 | 2026-07-01 | 2026-06-10 |
| Perfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye 0.1% Sodium Hyaluronate Eye Drops, Perfluorohexyloctane Eye Drops (PFHO) - Dry Eye | Phase 4 | Not yet recruiting | Beijing Tongren Hospital | 159 | 2026-06-30 | 2026-07-01 |
| A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo® Determine the ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to detect tear film stability utilizing Miebo® - Dry Eye | Phase 4 | Active not recruiting | The Eye Care Institute | 20 | 2026-06-26 | 2026-07-29 |
| Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5% - Dry Eye Disease (DED) | Phase 4 | Recruiting | Andover Research Eye Institute | 60 | 2026-06-03 | 2026-06-30 |
| Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction Vevye(Cyclosporine 0.1% Ophthalmic Solution) - Meibomian Gland Dysfunction (MGD) | Phase 4 | Recruiting | University of Alabama at Birmingham | 48 | 2026-06-01 | 2026-06-09 |
| A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK Miebo four times per day - Dry Eye Syndrome (DES), Dry Eye Disease (DED) | Phase 4 | Recruiting | Vance Thompson Vision | 100 | 2026-05-05 | 2026-06-24 |
| Vevye + Flarex Combination Therapy for Dry Eye Vevye(Cyclosporine 0.1% Ophthalmic Solution), Flarex - Dry Eye | Phase 4 | Enrolling by invitation | Canyon City Eyecare | 60 | 2026-04-03 | 2026-04-28 |
Showing 20 of 238. Sign in to see all of them.
Dry Eye Syndromes (218) · Sjogren's Syndrome (17) · Keratoconjunctivitis Sicca (11) · Meibomian Gland Dysfunction (10) · Cataract (9) · Glaucoma (6) · Arthritis, Rheumatoid (4) · Corneal Diseases (3) · Dacryocystitis (3) · Eye Diseases (3) · Inflammation (3) · Lacrimal Duct Obstruction (3) · Spondylarthritis (3) · Systemic Vasculitis (3)
Eye Diseases (235) · Immune System Diseases (23) · Skin and Connective Tissue Diseases (20) · Arthritis (18) · Autoimmune Diseases (18) · Connective Tissue Diseases (18) · Joint Diseases (18) · Mouth Diseases (18) · Musculoskeletal Diseases (18) · Stomatognathic Diseases (18) · Rheumatic Diseases (17) · Salivary Gland Diseases (17) · Xerostomia (15) · Arthritis, Rheumatoid (14)
Cyclosporins (17) · Ophthalmic Solutions (17) · lifitegrast (16) · Cyclosporine (15) · Lubricant Eye Drops (15) · Calcium Dobesilate (11) · Hyaluronic Acid (11) · Carboxymethylcellulose Sodium (9) · Dexamethasone (6) · Fluorometholone (5) · Loteprednol Etabonate (5) · perfluorohexyl-octan (5) · Sodium Chloride (4) · diquafosol (4) · rebamipide (4)
Innovative Medical (13) · Alcon Research (10) · Allergan (9) · Medical University of Vienna (9) · University of Alabama at Birmingham (8) · Southern College of Optometry (7) · Bausch & Lomb Incorporated (5) · Toyos Clinic (5) · University of Waterloo (5) · Peking University Third Hospital (4) · Research Insight LLC (4) · University of Sao Paulo General Hospital (4) · Chang Gung Memorial Hospital (3) · Gordon Schanzlin New Vision (3) · Massachusetts Eye and Ear Infirmary (3)
United States (118) · China (12) · Austria (10) · Canada (9) · Brazil (8) · South Korea (7) · Taiwan (6) · Spain (5) · Thailand (4) · Egypt (3) · France (3) · Italy (3) · Mexico (3) · United Kingdom (3) · India (2)
John Hovanesian, MD (4) · Pedram Hamrah, MD (4) · Lyndon Jones, PhD, FCOptom (3) · Barbara Burgos Blasco, MD, PhD (2) · Barry Schechter, MD (2) · Christopher Starr, MD (2) · Damon Dierker, OD, FAAO (2) · Gerhard Garhoefer, MD (2) · Hong Qi (2) · Jay Mashouf, OD (2) · Melissa Toyos, MD (2) · Ana Hervas Ontiveros, Dr (1) · Andrew Hopkinson, PhD (1)
PMID 14508260, PMID 10434857, PMID 10768324, PMID 10815152, PMID 11009316, PMID 11320025, PMID 11320034, PMID 11567963, PMID 11685055, PMID 11820911, PMID 11879137, PMID 12006334, PMID 12140209, PMID 12657587, PMID 14452301, PMID 14644218, PMID 14723108, PMID 15090417, PMID 15489495, PMID 15733983, PMID 15976462, PMID 16004673, PMID 16102833, PMID 16785864, PMID 16900272, PMID 16973668, PMID 17102664, PMID 17172891, PMID 17262232, PMID 17508121, PMID 17665393, PMID 18234997, PMID 18609466, PMID 18691081, PMID 18806663, PMID 18813071, PMID 18848318, PMID 19006483, PMID 19034126, PMID 19128374, PMID 19218606, PMID 19730088, PMID 20142967, PMID 20155706, PMID 20191499, PMID 20393114, PMID 20597641, PMID 20631232, PMID 21386741, PMID 21529354